Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-α) in the development of inflammatory bowel disease in mice
- 1 December 2004
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 84 (12) , 1643-1654
- https://doi.org/10.1038/labinvest.3700185
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat ModelLaboratory Investigation, 2003
- Activation of Peroxisome Proliferator–Activated Receptor-α Protects the Heart From Ischemia/Reperfusion InjuryCirculation, 2003
- Emerging biotherapies for inflammatory bowel diseaseEmerging Drugs, 2003
- Fibrates down-regulate IL-1–stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB–C/EBP-β complex formationBlood, 2003
- Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemie myocardiumPublished by Elsevier ,2002
- PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancerTrends in Pharmacological Sciences, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisPublished by Elsevier ,1999
- Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in ratsInflammation Research, 1993
- Specific repression of transthyretin gene expression in rat liver by a peroxisome proliferator clofibrateBiochemical and Biophysical Research Communications, 1992